Brought to you by 
Investors stake $31.5mm in iPierian
17 Jul 2009
Executive Summary
Stem cell therapeutics developer iPierian has received $31.5mm in a first round of financing from various backers. Kleiner Perkins Caufield & Byers and Highland Capital Partners together invested $20mm; MPM Capital, $10mm; and FinTech Capital Partners, $1.5mm. Representatives from each of the investors will take seats on the company's board. IPierian was recently formed through the merger of pluripotent stem cell companies iZumi Bio and Pierian to accelerate the development of new cardiovascular, metabolic, and neurology therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Investors stake $31.5mm in iPierian
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice